NewAmsterdam Pharma Company N.V. Overview
Pro stress-test →NewAmsterdam is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. The company is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Strategic Profile
Pro stress-test →Obicetrapib is being investigated in multiple clinical trials for cardiovascular disease applications and in Phase 2a clinical trial for Alzheimer's disease. The company maintains a focused pipeline centered on addressing cardiometabolic disease with oral therapies where existing treatment options are suboptimal. Strategic positioning emphasizes both cardiovascular and neurodegenerative indications with a single lead asset.
Competitive Landscape
Pro stress-test →NewAmsterdam competes in the CETP inhibitor and non-statin LDL-C lowering space against established players like Merck (Anacetrapib legacy work), Pfizer, and Roche. The broader cardiometabolic therapeutic landscape includes statins (Amgen, Regeneron, Sanofi) and emerging GLP-1 analogs. Obicetrapib's oral, once-daily profile and dual-indication potential (cardiovascular + Alzheimer's) represent differentiation, but efficacy and safety data from ongoing trials will be decisive versus existing alternatives.
Industry Context
NewAmsterdam Pharma Company N.V. operates in Clinical-stage biopharmaceuticals (cardiovascular/metabolic disease).
Key facts
Founded: 2019 · Headquarters: Naarden, Netherlands · Employees: Unknown · Revenue: $0 (pre-revenue) · Market cap: ~$3.55B